Animal Model >> Cntnap2 Details

contactin associated protein-like 2

image     
Summary
Gene Symbol Cntnap2
Gene Name contactin associated protein-like 2
Aliases 5430425M22Rik, Caspr2, mKIAA0868
Model Species Mus musculus
Model Type Genetic
Model Summary Axon-glia interactions mediated by Cntnap2 and Tag-1 s allow myelinating glial cells to organize ion channels in the underlying axonal membrane
Number of Reports 5
Number of Models 21
External Links Entrez Gene     MGI Logo     AllenBrainAtlas
ASD-associated variation model  Marker ASD
  References
Primary Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. Poliak S , et al. 2003 12963709
Primary Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Peagarikano O , et al. 2011 21962519
Additional Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. Horresh I , et al. 2010 20164332
Additional Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Peagarikano O , et al. 2011 21962519
Additional Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Peagarikano O , et al. 2015 25609168
Additional Cerebellar associative sensory learning defects in five mouse autism models. Kloth AD , et al. 2015 26158416
  Various Models
Marker
  construct
CNTNAP2_1_KO_d4.1_Tg
Horresh I , et al. 2010
Marker
  construct
CNTNAP2_2_KO_C2_Tg
Horresh I , et al. 2010
Marker
  construct
CNTNAP2_3_KO_HM
Horresh I , et al. 2010
Marker
  construct
CNTNAP2_4_KO_HM
Poliak S , et al. 2003
Marker
  construct
CNTNAP2_5_KO_HM
Kloth AD , et al. 2015 Peagarikano O , et al. 2015 Peagarikano O , et al. 2011
Marker
  construct
CNTNAP2_5_KO_HM_AVP-1
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_AVP-2
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_AVPR-Ant_AVP
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_DREADD-OXTN
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Fenobam
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Flumazenil
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Fluoxetine
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_MC4R-Ag
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_OXTR-Ant_AVP
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_OXTR-Ant_MC4R-Ag
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_OXTR-Ant_OXT
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Oxytocin-1
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Oxytocin-2
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Oxytocin-3
Peagarikano O , et al. 2015
Marker
  construct
CNTNAP2_5_KO_HM_Risperidone
Peagarikano O , et al. 2011
Marker
  construct
CNTNAP2_6_KO_HT
Kloth AD , et al. 2015 Peagarikano O , et al. 2011